The Menarini Group-Strategy, SWOT and Corporate Finance Report

The Menarini Group-Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.

Key Findings

Detailed information on The Menarini Group required for business and competitor intelligence needs

A study of the major internal and external factors affecting The Menarini Group in the form of a SWOT analysis

An in-depth view of the business model of The Menarini Group including a breakdown and examination of key business segments

Intelligence on The Menarini Group’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

News about The Menarini Group, such as business expansion, restructuring, and contract wins

Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons To Buy

Gain understanding of The Menarini Group and the factors that influence its strategies

Track strategic initiatives of the company and latest corporate news and actions

Assess The Menarini Group as a prospective partner, vendor or supplier

Support sales activities by understanding your customers’ businesses better

Stay up to date on The Menarini Group’s business structure, strategy and prospects

Key Highlights

The Menarini Group (Menarini or ‘the group’), a privately-held pharmaceutical business entity, is engaged in the development and manufacture of pharmaceutical products mainly for cardiovascular diseases; oncology; pain; inflammation; and asthma. The group primarily operates in Italy. It is headquartered in Florence, Italy and employed 16,457 people at the end of the year 2014.